Payment overview · 2025
General Payments
$213.88
10 reported records · 8 companies
Healthcare provider profile · identity verified
Bradford A Bergman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREAT FALLS, MT · NPI 1235130113
Verified facts
What the public records show
CMS Open Payments records show Bradford A Bergman, MD received $213.88 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.11 | 24.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.44 | 15.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.08 | 13.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.35 | 10.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.41 | 10.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.80 | 9.3% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.86 | 8.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.83 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.88 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 998 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 761 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 134 |
| Lisinopril | Lisinopril | 435 | 112 |
| Potassium Chloride | Potassium Chloride | 434 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 371 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 91 |
| Chlorthalidone | Chlorthalidone | 322 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 282 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 72 |
| Losartan Potassium | Losartan Potassium | 278 | 67 |
| Omeprazole | Omeprazole | 272 | 46 |
| Metformin Hcl | Metformin Hcl | 245 | 64 |
| Eliquis | Apixaban | 222 | 55 |
| Irbesartan | Irbesartan | 208 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 48 |
| Simvastatin | Simvastatin | 204 | 48 |
| Gabapentin | Gabapentin | 197 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 54 |
| Furosemide | Furosemide | 173 | 42 |
| Allopurinol | Allopurinol | 166 | 43 |
| Ozempic | Semaglutide | 160 | 24 |
| Metformin Hcl Er | Metformin Hcl | 150 | 35 |
| Tramadol Hcl | Tramadol Hcl | 149 | 34 |
| Montelukast Sodium | Montelukast Sodium | 148 | 28 |
| Finasteride | Finasteride | 142 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 30 |
| Ezetimibe | Ezetimibe | 130 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 31 |
| Spironolactone | Spironolactone | 127 | 37 |
| Sertraline Hcl | Sertraline Hcl | 124 | 22 |
| Carvedilol | Carvedilol | 122 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 23 |
| Donepezil Hcl | Donepezil Hcl | 107 | 21 |
| Lorazepam | Lorazepam | 105 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 28 |
| Warfarin Sodium | Warfarin Sodium | 100 | 16 |
| Trazodone Hcl | Trazodone Hcl | 94 | 26 |
| Xarelto | Rivaroxaban | 90 | 14 |
| Farxiga | Dapagliflozin Propanediol | 89 | 20 |
| Mirtazapine | Mirtazapine | 86 | 11 |
| Jardiance | Empagliflozin | 83 | 21 |
| Famotidine | Famotidine | 81 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 19 |
| Bupropion Xl | Bupropion Hcl | 61 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 13 |
| Prednisone | Prednisone | 57 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 16 |
| Celecoxib | Celecoxib | 48 | 14 |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Pregabalin | Pregabalin | 46 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Atenolol | Atenolol | 43 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Valacyclovir | Valacyclovir Hcl | 39 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Nystatin | Nystatin | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Savaysa | Edoxaban Tosylate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.88 · 10 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, EVENITY, Ohtuvayre, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, XYWAV | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error